Zydus Cadila has received the final approval from the USFDA to market Oxybutynin Chloride Extended-Release Tablets in the strengths of 5 mg, 10 mg, and 15mg.
The drug is used to treat symptoms of overactive bladder and urinary incontinence (urine leakage) and will be produced at the group's formulation manufacturing facility at Moraiya in Ahmedabad. The estimated sale for Oxybutynin Chloride Extended-Release Tablets is $150.9 million (Source: IMS Health, IMS National Sales Perspective Audit, MAT April 2017, extracted June 2017.
The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.529 as compared to the previous close of Rs. 525.5. The total number of shares traded during the day was 70820 in over 1691 trades.
The stock hit an intraday high of Rs. 532.2 and intraday low of 524.05. The net turnover duri ng the day was Rs. 37331875.
Source: Zydus receives final approval from the USFDA for Oxybutynin Chloride Extended-Release Tablets
No comments:
Post a Comment